iPSC Expansion & Quality Control (QC)

The contract involves the expansion of gene-edited induced pluripotent stem cell (iPSC) lines along with conducting standardized quality control testing to ensure their integrity and suitability for further use. Key quality control measures include assessments of pluripotency, karyotyping to detect chromosomal abnormalities, and contamination screening to confirm the absence of microbial presence. The work will be performed at a site located in Bar Harbor, with a specified deadline for responses set for June 23, 2026. This subcontract is issued by the National Institutes of Health under the Department of Health and Human Services. It falls under the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. The contract aims to support rigorous quality standards for gene-edited iPSC lines, critical for downstream research and therapeutic applications. While no specific set-aside or particular organization type was indicated, the contract ensures standardized procedures conducive to reproducibility and reliability in stem cell research.